Neuropace Inc reports results for the quarter ended in December - Earnings Summary

NeuroPace

05/03/2024 23:38

* Neuropace Inc  NPCE.OQ  reported a quarterly adjusted loss
of 23
cents​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of -45
cents.  The mean expectation of six analysts for the quarter was
for a loss of 31 cents per share. Wall Street expected
results to range from -36 cents to -25 cents per share.
    * Revenue rose 40.8% to $18.01 million from a year ago;
analysts
expected $17.46 million. 
    * Neuropace Inc's reported EPS for the quarter was a loss
of 23
cents​.
    * The company reported a quarterly loss of $6.2 million.
    * Neuropace Inc shares had risen by 34.5% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Neuropace Inc is
$16.00 
This summary was machine generated from LSEG data March 5 at
11:37 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.31          -0.23          Beat
 Sep. 30 2023      -0.41          -0.28          Beat
 Jun. 30 2023      -0.46          -0.36          Beat
 Mar. 31 2023      -0.46          -0.41          Beat